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The murine embryo has become a valuable tool to examine the ontogeny of hematopoiesis. However, the
onset of the systemic circulation has long been a confounding developmental variable that may mask the
site of blood cell emergence. This Minireview examines some approaches that have been applied to
overcome this obstacle.Introduction
Hematopoietic stem cells (HSC) are defined as cells displaying
the ability to differentiate into all the various blood cell lineages
and to self-renew to sustain hematopoiesis throughout the life
of the subject. The first HSCs are generated during embryonic
development, with expansion and then migration through the
bloodstream to seed the fetal liver, and subsequently, the bone
marrow, where blood cells are produced throughout adult life.
The stem cell theory of hematopoiesis predicts that all mature
hematopoietic elements arise from a HSC via a hierarchical pro-
gression of progenitor cell intermediates that display irrevocable
changes in the balance between proliferative potential and differ-
entiation. The search for the first HSC to emerge during embry-
onic development should, therefore, logically start with the
search for the first appearance of blood cells.
The first hematopoietic cells to appear in the developing
murine embryo emerge within the extraembryonic yolk sac (YS)
blood islands at embryonic day 7.5 (E7.5) (Moore and Metcalf,
1970). These nucleated erythrocytes express embryonic globins
and emerge from distinct progenitor cells in a process called
primitive erythropoiesis. The first erythroid progenitors that
produce enucleated erythrocytes expressing adult hemoglobin
molecules (called definitive erythroid progenitor cells) appear in
the YS on E8.25 (Palis et al., 1999). Definitive hematopoietic
progenitor cells, including mixed lineage and high proliferative
potential colony-forming cells, first emerge in the YS, followed
by cells in the bloodstream and within the embryo in the para-
aortic splanchnopleura region (P-Sp) (Palis et al., 1999). Such
a pronounced appearance of blood cells should theoretically
herald HSC emergence.
Historical Overview of Searching for the Origin
of HSC Activity in the Embryo
Results from early studies conducted in chick embryos were in-
deed consistent with the hypothesis that hematopoiesis and the
first HSC emerge in the YS (Moore and Owen, 1967). However,
chick-quail chimera analysis revealed that the contribution of
YS to hematopoiesis was only transient and that only intraem-
bryonic cells were able to provide long-term reconstitution
(LTR) (Dieterlen-Lievre, 1975). Similarly, the first cells that can
engraft a lethally irradiated adult mouse and provide long-term
multilineage reconstitution have been shown to be present within
the intraembryonic compartment in a region called the Aorta-Gonad-Mesonephros (AGM) of E10.5 embryos (reviewed in
Dzierzak and Speck, 2008), with LTR HSC activity emerging
slightly later at E11.0 to E11.5 in the YS, fetal liver, and placenta
(Gekas et al., 2005; Ottersbach and Dzierzak, 2005). However,
when myeloablated newborn pups were used as recipients (be-
cause the liver was still an active hematopoietic site and, thus,
provided an environment consistent with the normal pattern of
blood cell migration and organ seeding in utero), both YS and
P-Sp cells from E9.0 embryos were capable of multilineage
LTR activity into primary newborn and secondary adult recipient
mice (Yoder et al., 1997). These results suggested that repopu-
lating HSC may emerge in more than one site early in develop-
ment but are detected somewhat later than the first hematopoi-
etic progenitor cells (a deviation from the stem cell theory of
hematopoiesis).
The major limitation in assessing the temporal and spatial
emergence of HSC is the fact that LTR HSC activity, tested in
either adult or neonatal recipients, is not detectable within the
embryo proper, YS, or other hematopoietic tissues until long af-
ter the heart has begun to beat and initiate blood cell redistribu-
tion throughout the systemic circulation. Obviously, defining the
origin of a circulating cell population is nearly impossible using
standard reductionist approaches. To circumvent this variable,
investigators have adopted several different strategies that
include explant culture of tissues isolated prior to initiation of
a heartbeat (precirculation), use of murine mutants in which no
heartbeat develops to examine spatial emergence of hematopoi-
etic progenitor cells, and lineagemarking strategies wheremark-
ing of a putative stem cell precursor occurs prior to systemic
blood circulation.
Demonstrating Hematopoietic Potential:
The Role of Stromal Cells
To avoid problems of interpretation inducedby the onset of blood
cell circulation, several investigators have isolated embryonic
tissues precirculation and examined hematopoietic cell emer-
gence in vitro. Matsuoka et al. reported that precursors for adult
repopulating HSCs were present in both YS and P-Sp regions at
E8.5, when YS and P-Sp cells were isolated from the precircula-
tion embryo and cocultured in a stromal microenvironment
derived from the AGM region (Matsuoka et al., 2001). With only
a 4 day in vitro coculture period, both YS and P-Sp cells devel-
oped the capacity to home and engraft in the bone marrow ofCell Stem Cell 3, December 4, 2008 ª2008 Elsevier Inc. 583
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and molecular mechanism for this stromal cell effect has not
been published. Cumano et al. showed that E8.5 P-Sp explants
maintained ex vivo for 2 days and then transferred as a cell
suspension onto a bone marrow-derived stromal cell line were
capable of multilineage LTR in adult rag2gc/ hosts (Cumano
et al., 2001). However, cultured YS cells could only provide
short-termmyelo-erythroid reconstitution and could not repopu-
late the lymphoid lineages. Thus, determination of the potential of
precirculation YS and P-Sp tissues for evidence of HSC-depen-
dent multilineage differentiation may be dependent upon the
unique characteristics of the stromal cells used in the coculture
setting.
A Mutant Mouse without a Heartbeat Serves
as a Novel Reagent for Hematopoiesis
If one were able to find a mutant mouse in which the embryo de-
veloped normally in the absence of circulating blood cells, one
could be more assured that the cells isolated in a particular tis-
sue emerged from that tissue. Of course, no embryo can survive
without a circulatory system through approximately E11.0 since
the organs and tissue become too large for sufficient diffusion of
oxygen and nutrients and removal of waste products to sustain
embryo survival. Ncx1 is a ubiquitously expressed sodium-
calcium exchanger that is expressed only in the heart during
embryogenesis and is required for initiation of a heartbeat.
ncx1 gene-deficient embryos develop normally until E10.0, but
die around E11.5 since the circulation is never established in
these embryos (Koushik et al., 2001). Thus, in a recent report,
ncx1 null (ncx1/) embryos provided a window of opportunity
to separately analyze the hematopoietic potential of YS and
P-Sp cells under a circulation-free environment (Lux et al.,
2008). The number of primitive erythroid progenitor cells was
normal in ncx1/ YS cells compared to WT YS cells, and prim-
itive erythroblasts were found only in the YS, not in the ncx1/
embryo proper as expected, since the YS is known to be the
only site for primitive erythroblast emergence. Although the total
number of definitive hematopoietic progenitors within the whole
embryonic tissues of ncx1/, ncx+/, and WT embryos was not
significantly different, essentially all of the definitive hematopoi-
etic progenitor cells were restricted to the vasculature of the
ncx1/ YS. Indeed, the YS was engorged with blood cells while
the embryo proper was nearly devoid of blood cells. This finding
demonstrated a YS origin for essentially all the hematopoietic
progenitor cells that seed the fetal liver before E10, as previously
predicted (Palis et al., 1999).
The placenta is another hematopoietic niche in which HSC
activity is readily detectable around E11.0 and greatly expands
over the next 2 to 3 days (Gekas et al., 2005). Rhodes et al
have examined de novo hematopoietic potential of the placenta
in the absence of circulation in WT and ncx1 null embryos
(Rhodes et al., 2008). In the ncx1/ placenta, CD41+ clusters
were found in the vessels of the chorioallantoic mesenchyme
and developing labyrinth, consistent with de novo emergence
of hematopoietic cells. Isolation of tissues from E8.5 to E9.5
ncx1/ and WT embryos, and subsequent coculture with OP9
or OP9-Delta-like 1(OP9-DL1), revealed that the placenta, as
well as YS and embryo proper (including P-Sp), showed similar
potentials for the development of erythro-myeloid and B and T584 Cell Stem Cell 3, December 4, 2008 ª2008 Elsevier Inc.lymphoid cells in WT and ncx1/ embryos. These findings indi-
cate the independent emergence and existence of multipotent
hematopoietic progenitors and putative HSC potential in the
E9.5 placenta as well as the YS and P-Sp. However, direct
evidence for the LTR activity of E9.5 ncx1/ YS, P-Sp, and
placental cells has not yet been reported using transplantation
assays in adult or neonatal hosts. Such assays will be required
to determine whether HSCs emerge independently in each he-
matopoietic site. Additional studies to identify the consequences
of a lack of blood flow on the specification of vascular endothelial
cells and the impact this plays in the emergence of HSC will also
be required.
Developing Cell-Marking Systems to Define the Origins
of Hematopoietic Cells
In order to directly approach the temporal and spatial origin of
blood cells in situ, several cell-tracking or cell-marking systems
have been developed that permit cells to emerge in their normal
microenvironment and not in a cocultured situation in vitro. Su-
giyama et al. generatedmouse chimeras by grafting donor green
fluorescent protein-expressing (GFP+) YS tissue into the YS of
host embryos before circulation commenced in a whole-embryo
culture system and traced the donor GFP+ YS cells for 66 hr in
the host embryos (Sugiyama et al., 2007). GFP+ cells circulated
into the host embryo and donor YS-derived erytho-myeloid
and CD19+ B cells emerged in the host chimeras, demonstrating
the existence of myeloid and some lymphoid potential in the YS
before circulation commences.
CD41 is a cell-surface integrin enriched in megakaryocyte and
platelet cells that is also expressed in hematopoietic progenitors
in the murine YS and in HSCs in the AGM region, fetal liver, and
adult bone marrow. CD41 promoter-driven Cre recombinase
micewere generated as ameans to identify theHSC and progen-
itors expressing this integrin in vivo when crossed with a reporter
mouse strain (Emambokus and Frampton, 2003). Beta-galacto-
sidase (b-gal) detection revealed CD41+ cells contributing to
embryonic and fetal progenitor cells and, even to some extent,
to the adult HSC fraction. However, the limited expression in
adult marrow blood cells suggests that the majority of marrow
HSC do not emerge from a CD41+ embryonic cell precursor.
The proposal that some endothelial cells give rise to hemato-
poietic cells (hemogenic endothelium) is suggested based in part
upon the observation of hematopoietic cell emergence from the
dorsal aorta inmurine embryos (Nishikawa et al., 1998). The clus-
ters budding from the aortic endothelium are believed to be
HSCs because of the lack of these clusters in the AGM region
in runx1-deficient mutant embryos where HSC activity fails to
emerge (North et al., 2002). Conditional runx1 deletion in cells
expressing TEK/Tie-2, a receptor for angiopoietin-1 expressed
in endothelial cells, also resulted in embryonic lethality similar to
runx1-deficient embryos (Li et al., 2006), supporting a role for
hemogenic endothelium in putative HSC emergence. However,
determination of the spatial origin of the specific endothelium
giving rise to HSC remained elusive using such a ubiquitous
endothelial promoter.
Samokhvalov et al. (Samokhvalov et al., 2007) developed an
advanced cell-tracking system and focused on the earliest
emergence of labeled cells in themurine embryo. In their system,
temporal Runx1 expression in the embryo was labeled with lacZ
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dams (the inactivated allele does not influence embryo survival).
Utilizing the restricted Runx1-lacZ expression pattern in the E7.5
YS compartment, those labeled cells that arose and resided in
the YS blood islands at E7.5 were subsequently traced through-
out embryogenesis and into adulthood via continuous cellular
lacZ expression. Thus, Runx1+ cells at E7.5 YS were shown to
contribute to the endothelium and endothelium-associated
hematopoietic clusters in the dorsal aorta where HSC activity
has been demonstrated to emerge. In addition, erythroid, mye-
loid, and B and T lymphoid cells in later stages of embryonic
development, as well as much of the HSC fraction in adult BM,
were identified as labeled YS derivatives. These findings indicate
that precirculation YS precursors contribute to the long-lived
adult marrow HSC compartment. However, these studies are
not without some controversy given questions about the half-
life and distribution of the injected tamoxifen in the dams and
the sensitivity of staining for rare, potentially labeled cells in the
P-Sp and allantoic regions.
In this issue, Zovein et al. have reported that the endothelium
lining the ventral wall of the aorta is responsible for HSC emer-
gence in the AGM region and that this hemogenic endothelium
is derived from a transient mesenchymal population. To arrive
at these conclusions, the authors employed several lineage-
tracing approaches (Zovein et al., 2008). A constitutive vascular
endothelial-cadherin (VE-cadherin) promoter-driven Cre recom-
binase expressing transgenic mouse line was crossed with the
ROSA26R (R26R) reporter transgenic mouse line to mark endo-
thelial cells and their derivatives. Constitutive VE-cadherin Cre
X R26R progeny displayed b-gal activity throughout the vascula-
ture of E10.5 embryos, including the endothelium of the ventral
wall of the dorsal aorta in the AGM region. At E13.5, progeny
from this mating displayed marked cells in 20%–40% of the
hematopoietic and most of the endothelial cells in the fetal liver,
despite VE-cadherin protein expression being restricted largely
to endothelial cells (and not hematopoietic cells). The marked
progeny were also resident in 20%–80% of the adult bone
marrow cells (again, far in excess of the reported frequency of
cells expressing VE-cadherin protein). These data suggested
that the hematopoietic cells were progeny derived from earlier
VE-cadherin-expressing cells.
Subsequently, the authors chose to move to tamoxifen-induc-
ible VE-cadherin Cre X R26Rmatings to restrict the Cre recombi-
nation and cell marking tomore specific time points in an attempt
to find a point at which AGM, and not YS vessels, were marked.
Surprisingly, induction with tamoxifen administration to the preg-
nant dams on E9.5 resulted in limited labeling of the vitelline and
umbilical arterial endothelium but caused significant labeling of
the AGM aortic endothelium and associated hematopoietic cells
budding from the aortic endothelium. Labeled endothelial and
hematopoietic cells were identified in the fetal liver at E14.5
and in a portion of erythroid, myeloid, T and B lymphoid, and
HSC subsets within the bone marrow of mice up to 13 months
of age, demonstrating that a temporally induced population of
AGM region endothelial cells expressing VE-cadherin produced
marked progeny with adult marrow HSC activity. Additional
experiments using smooth muscle 22 alpha promoter-driven
Cre or myocardin promoter-driven Cre transgenic mouse lines
crossed with the R26R lines demonstrated that early subaorticmesenchyme contributes to AGM aortic endothelium and adult
bone marrow cells, while later subaortic mesenchyme fails to
label either endothelium or hematopoietic cells. Thus, only the
early and transient AGM mesenchyme population that gives
rise to AGM aortic endothelium has the capacity to produce
HSC progeny and appears to do so through an endothelial
intermediate.
It is apparent that not all adult bonemarrowhematopoietic cells
were derivatives of a VE-cadherin-expressing precursor in the
present studies. Is this a reflection of some HSC arising from
a nonvascular/non-VE-cadherin+ precursor or a result of the
VE-cadherin promoter not functioning optimally in all hemogenic
endothelial cells in the various tissues during development? It is
also apparent that VE-cadherin+ endothelium of the AGM, pla-
centa, and YS all produced hematopoietic cells at E10.5–E12.5,
long after the commencement of the systemic circulation. Thus,
further studies using inducible tissue-specific (AGM, placenta,
YS), hemogenic endothelial-restricted, promoter-driven Cre
transgenic lines may be required to assess the overall contribu-
tions of the HSC derived from each of these unique sites to the
adult marrow pool. To generate such reagents, further work will
be required to prospectively isolate the hemogenic endothelium
from each site to delineate the unique features that distinguish
these cells from the other endothelial cells present in these tis-
sues. Once tissue-specific hemogenic endothelial cells are iso-
lated, investigators will be able to more thoroughly investigate
the genetic regulatory networks that permit hematopoietic cells
to emerge from the hemogenic endothelium. Such information
may be of great interest to investigators attempting to differenti-
ate HSC from embryonic stem cells or induced pluripotent stem
cells, where induction of certain smooth muscle 22 alpha-
expressing mesoderm subsets and hemogenic endothelium
may be the first requirements in seeking differentiation pathways
converging to HSC emergence.
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